Overview

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Phosphodiesterase 5 Inhibitors